Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merck & Company Inc. | KEYTRUDA (KEYNOTE-564) | Renal cell carcinoma (RCC) | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | Ifinatamab deruxtecan (DS-7300) - (IDeate-Lung02 ) | Extensive-stage small cell lung cancer (SCLC) | Phase 3 | Enrollment Initiation | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) - (AMBASSADOR (A031501) KEYNOTE-123) | Localized muscle-invasive urothelial carcinoma (MIUC) | Phase 3 | Data Released | Intravenous | Oncology |
| Merck & Company Inc. | KEYTRUDA plus LENVIMA versus docetaxel - (LEAP-008) | Metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Intravenous and oral | Oncology |
| Merck & Company Inc. | KEYTRUDA plus LENVIMA in combination with pemetrexed (Alimta) - (LEAP-006) | Nonsquamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| Merck & Company Inc. | Sotatercept - (SOTERIA) | Pulmonary arterial hypertension (PAH) | Phase 3 | Data Released | Subcutaneous | Cardiology |
| Merck & Company Inc. | KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) - (LEAP-010) | Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 3 | Intravenous and oral | Oncology | |
| Merck & Company Inc. | MK-0616 - (CORALreef Outcomes) | Cardiovascular risk, Hypercholesterolemia | Phase 3 | Enrollment Initiation | Oral | Cardiology |
